ATE373077T1 - Verfahren zur herstellung von cs6- antigenimpfstoff zur behandlung, vorbeugung oder hemmung enterotoxigener escherichia coli- infektionen - Google Patents

Verfahren zur herstellung von cs6- antigenimpfstoff zur behandlung, vorbeugung oder hemmung enterotoxigener escherichia coli- infektionen

Info

Publication number
ATE373077T1
ATE373077T1 AT03709279T AT03709279T ATE373077T1 AT E373077 T1 ATE373077 T1 AT E373077T1 AT 03709279 T AT03709279 T AT 03709279T AT 03709279 T AT03709279 T AT 03709279T AT E373077 T1 ATE373077 T1 AT E373077T1
Authority
AT
Austria
Prior art keywords
treating
preventing
methods
escherichia coli
enterotoxigenic escherichia
Prior art date
Application number
AT03709279T
Other languages
English (en)
Inventor
Frederick Cassels
James Wood
Original Assignee
Us Army Medical Res & Materiel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Army Medical Res & Materiel filed Critical Us Army Medical Res & Materiel
Application granted granted Critical
Publication of ATE373077T1 publication Critical patent/ATE373077T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03709279T 2002-02-25 2003-02-24 Verfahren zur herstellung von cs6- antigenimpfstoff zur behandlung, vorbeugung oder hemmung enterotoxigener escherichia coli- infektionen ATE373077T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36110502P 2002-02-25 2002-02-25
US42180402P 2002-10-29 2002-10-29

Publications (1)

Publication Number Publication Date
ATE373077T1 true ATE373077T1 (de) 2007-09-15

Family

ID=27807904

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03709279T ATE373077T1 (de) 2002-02-25 2003-02-24 Verfahren zur herstellung von cs6- antigenimpfstoff zur behandlung, vorbeugung oder hemmung enterotoxigener escherichia coli- infektionen

Country Status (7)

Country Link
US (1) US7217541B2 (de)
EP (1) EP1481053B1 (de)
AT (1) ATE373077T1 (de)
AU (1) AU2003213233B2 (de)
CA (1) CA2477273A1 (de)
DE (1) DE60316258D1 (de)
WO (1) WO2003076643A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1372708T3 (da) * 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre
US20040208928A1 (en) * 2003-04-15 2004-10-21 Animal Technology Institute Taiwan Method for preparing an orally administrable formulation for controlled release
EP1543836A1 (de) * 2003-12-17 2005-06-22 Berna Biotech AG Rekombinante Stamm von Vibrio cholerae und Impfstoff, der diesem Stamm enthält
KR101940357B1 (ko) 2011-09-12 2019-01-18 스칸디나비안 바이오파마 홀딩 에이비 세포 표면 상 ｅｔｅｃ ｃｓ６ 항원 제시의 증가 방법 및 그것의 수득가능한 산물들
EP2897638A1 (de) 2012-09-24 2015-07-29 Montana State University-Bozeman Rekombinanter lactococcus lactis zur expression des escherichia coli-kolonisationsfaktor-antigens i (cfa/i) fimbriae und verfahren zu deren verwendung
JP7109882B2 (ja) 2016-02-15 2022-08-01 モダン メドウ，インコーポレイテッド コラーゲンフィブリルを含むバイオファブリケーテッド材料を作製するための方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
EP0453024B1 (de) * 1990-04-20 1995-05-31 Akzo Nobel N.V. Untereinheit-Impfstoff gegen Actinobacillus Pleuropneumoniae
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
US7118758B1 (en) * 1997-01-24 2006-10-10 The United States Of America As Represented By The Secretary Of The Army Transformed bacteria producing CS6 antigens as vaccines
SE9401921D0 (sv) * 1994-06-03 1994-06-03 Sbl Vaccin Ab A method of cultivating bacteria
US5698416A (en) 1995-06-02 1997-12-16 The United States Of America As Represented By The Secretary Of The Army Methods for production of antigens under control of temperature-regulated promotors in enteric bacteria
US5914114A (en) * 1995-06-02 1999-06-22 The United States Of America As Represented By The Secretary Of The Army Method of raising antibodies against E. coli of the family CS4-CFA/I
HUP0300297A3 (en) * 2000-04-20 2005-09-28 Univ Maryland Baltimore Baltim Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same
DK1372708T3 (da) * 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre

Also Published As

Publication number Publication date
WO2003076643A2 (en) 2003-09-18
US7217541B2 (en) 2007-05-15
AU2003213233A1 (en) 2003-09-22
EP1481053A2 (de) 2004-12-01
DE60316258D1 (de) 2007-10-25
EP1481053A4 (de) 2005-06-22
WO2003076643A3 (en) 2004-09-10
CA2477273A1 (en) 2003-09-18
EP1481053B1 (de) 2007-09-12
AU2003213233B2 (en) 2009-02-05
US20040005662A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
ATE529409T1 (de) Verfahren zur herstellung von kristallinen aripiprazolformen
HUP0100723A2 (hu) Indolszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
NO990362D0 (no) Nye stammer av Echerichia coli, metoder for fremstilling og bruk av disse i fermenteringsprosesser for produksjon av L-treonin
RU94046367A (ru) Днк, хозяйская клетка, способ получения белка, белок, фармацевтический препарат, антитело, применение антитела
ATE17082T1 (de) Verfahren zur herstellung von polysaccharidprotein-komplexenaus bakterienhuellen, die hergestellten produkte und dieselben enthaltende immunogenische zusammensetzungen.
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
DE69635783D1 (de) Antigen omp26 aus haemophilus influenzae
GB0313916D0 (en) Vaccine composition
CY1106926T1 (el) Γονιδιο που κωδικοποιει την ηλιομυκινη και η χρηση της
ATE87003T1 (de) Oligosaccharide, immunogene und impstoffe und verfahren zur herstellung dieser oligosaccharide, immunogene und impstoffe.
ATE373077T1 (de) Verfahren zur herstellung von cs6- antigenimpfstoff zur behandlung, vorbeugung oder hemmung enterotoxigener escherichia coli- infektionen
BRPI0415010A8 (pt) forma cristalina, composto, processo para preparar os mesmos, métodos para tratar uma condição associada com excesso de taquicininas, uso do composto cristalino, e, composição farmacêutica
EA200600778A1 (ru) 1,3-диметилбутилкарбоксанилиды для борьбы с нежелательными микроорганизмами
ATE476982T1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
EP0347682A3 (de) Polycarbonate mit mesogenen Verbindungen als Endgruppen, ihre Herstellung und Verwendung
ATE491463T1 (de) Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
DE602004023100D1 (de) Verbindungen und verfahren zur behandlung von dyslipidemie
GB943841A (en) Zeolite catalyzed condensation process for producing organosilicon polymers
ATE209914T1 (de) Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
ATE454383T1 (de) Neue verbindungen, deren verwendung und herstellung
EA200501244A1 (ru) Оксатиинкарбоксамиды
DE60319553D1 (de) Wodka und verfahren zur herstellung von wodka
ATE190492T1 (de) Verwendung von gift aus hautflüglern (hymenopteren) zur herstellung eines medikamentes zur behandlung von infektionen durch dna-viren
ATE325886T1 (de) Verfahren zur herstellung von d-pantothensäure und/oder ihren salzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties